share_log

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Short Interest Update

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Short Interest Update

芬奇治療集團(納斯達克市場代碼：FNCH)空頭股數更新
kopsource ·  2022/08/03 12:41

Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 285,900 shares, a drop of 24.5% from the June 30th total of 378,600 shares. Based on an average daily volume of 968,000 shares, the short-interest ratio is currently 0.3 days. Currently, 1.9% of the shares of the company are sold short.

芬奇治療集團公司(納斯達克代碼：FNCH-GET評級)是空頭股數7月份大幅下降的目標。截至7月15日，空頭股數共有28.59萬股，較6月30日的37.86萬股下降了24.5%。以日均成交量9.68,000股計算，短息比率目前為0.3天。目前，該公司1.9%的股份被賣空。

Finch Therapeutics Group Stock Performance

芬奇治療集團股票表現

Finch Therapeutics Group stock traded up $0.17 during midday trading on Wednesday, reaching $2.07. 5 shares of the company's stock were exchanged, compared to its average volume of 39,337. Finch Therapeutics Group has a 52 week low of $1.71 and a 52 week high of $17.39. The firm has a market cap of $98.45 million, a price-to-earnings ratio of -1.43 and a beta of -0.52. The stock's 50-day simple moving average is $2.44 and its 200 day simple moving average is $4.50.

芬奇治療集團的股票在週三午盤交易中上漲0.17美元，達到2.07美元。該公司股票的交易量為5股，而其平均成交量為39,337股。芬奇治療集團的52周低點為1.71美元，52周高點為17.39美元。該公司市值為9845萬美元，市盈率為-1.43，貝塔係數為-0.52。該股的50日簡單移動均線切入位在2.44美元，200日簡單移動均線切入位在4.50美元。

Get
到達
Finch Therapeutics Group
芬奇治療集團
alerts:
警報：

Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.52) EPS for the quarter. The business had revenue of $0.35 million for the quarter. Finch Therapeutics Group had a negative return on equity of 33.13% and a negative net margin of 448.35%. Research analysts forecast that Finch Therapeutics Group will post -1.98 earnings per share for the current year.

芬奇治療集團(納斯達克代碼：FNCH-GET Rating)最近一次公佈季度收益是在5月16日星期一。該公司公佈了該季度每股收益(0.52美元)。該業務本季度的收入為35萬美元。芬奇治療集團的淨資產回報率為負33.13%，淨利潤率為負448.35%。研究分析師預測，芬奇治療集團本年度每股收益將達到1.98美元。

Institutional Investors Weigh In On Finch Therapeutics Group

機構投資者看好芬奇治療集團

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in Finch Therapeutics Group by 19.4% during the first quarter. Renaissance Technologies LLC now owns 45,000 shares of the company's stock worth $226,000 after acquiring an additional 7,314 shares during the last quarter. BlackRock Inc. lifted its position in Finch Therapeutics Group by 2.3% during the first quarter. BlackRock Inc. now owns 404,931 shares of the company's stock worth $2,038,000 after acquiring an additional 9,149 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Finch Therapeutics Group by 53.6% during the first quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company's stock worth $189,000 after acquiring an additional 13,128 shares during the last quarter. Light Street Capital Management LLC lifted its position in Finch Therapeutics Group by 1.8% during the fourth quarter. Light Street Capital Management LLC now owns 811,731 shares of the company's stock worth $8,093,000 after acquiring an additional 14,400 shares during the last quarter. Finally, SCS Capital Management LLC acquired a new stake in Finch Therapeutics Group during the fourth quarter worth approximately $382,000. 22.68% of the stock is currently owned by institutional investors and hedge funds.
幾家對衝基金最近買賣了該股的股票。文藝復興技術公司在第一季度將其在芬奇治療集團的地位提高了19.4%。復興科技有限責任公司在上個季度增持了7,314股後，現在擁有45,000股該公司股票，價值226,000美元。貝萊德股份有限公司在第一季度將其在芬奇治療集團的頭寸提高了2.3%。貝萊德股份有限公司在上個季度增持了9,149股後，目前持有404,931股該公司股票，價值2,038,000美元。Qube Research&Technologies Ltd在第一季度將其在Finch治療集團的地位提高了53.6%。Qube Research&Technologies Ltd在上個季度額外收購了13,128股後，現在擁有37,631股該公司股票，價值18.9萬美元。Light Street Capital Management LLC在第四季度將其在芬奇治療集團的頭寸提高了1.8%。Light Street Capital Management LLC現在擁有811,731股該公司的股票，價值8,093,000美元，在上個季度又收購了14,400股。最後，SCS資本管理有限責任公司在第四季度收購了芬奇治療集團價值約38.2萬美元的新股份。22.68%的股票目前由機構投資者和對衝基金持有。

About Finch Therapeutics Group

芬奇治療集團簡介

(Get Rating)

(獲取評級)

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.

芬奇治療集團公司是一家臨牀階段的微生物組治療公司，在美國開發一種新型的口服生物藥物。該公司的主要候選藥物是CP101，這是一種口服微生物膠囊，正處於第三階段臨牀試驗，用於治療反覆發作的艱難梭菌感染患者，以及治療慢性乙肝病毒。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
  • Is Starbucks Shooting For The Moon?
  • PayPal Continues To Struggle As Competition Increases
  • Two High-Yield Deep-Values You Shouldn't Ignore
  • Proposed Tesla Stock Split Drives EV Market Higher
  • Caterpillar Falls To Strong Support Near Bottom Of Range
  • 免費獲取StockNews.com關於芬奇治療集團(FNCH)的研究報告
  • 星巴克是在向月球進軍嗎？
  • PayPal繼續掙扎，競爭加劇
  • 你不應該忽視的兩個高收益深度價值
  • 擬議的特斯拉股票拆分推動電動汽車市場走高
  • 卡特彼勒跌至接近區間底部的強勁支撐

Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.

接受芬奇治療集團每日新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收芬奇治療集團和相關公司的最新新聞和分析師評級的每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論